| Management target | Revenue 10.0% |
|---|
| Revenue growth | 2% YoY revenue growth, severely muted by CMO supply constraints. |
|---|---|
| Margins | EBITDA margins improved significantly by 290 basis points to 34%. |
| Demand visibility | Strong demand for shingles vaccine and specialty respiratory products like Nucala. |
| Management confidence | Confident but cautious; focused on pivoting towards specialty and oncology portfolios. |
Growth
PAT grew 10% YoY and EBITDA 11%, driven by higher gross margins and AI-led operational efficiencies.
Outlook
Management maintains an ambitious double-digit growth target for the coming years, supported by 26 clinical trials.
Risks
Continued supply chain fragility and high exposure to NLEM pricing regulations remain key structural risks.
Earnings Call Transcript filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,755.00
- Market cap
- ₹46,671 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 43.7×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Legal & Regulatory
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
- Value
- ₹94.09 Cr